TY - JOUR
T1 - Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment
AU - Valdez-Cruz, Norma A.
AU - García-Hernández, Enrique
AU - Espitia, Clara
AU - Cobos-Marín, Laura
AU - ALTAMIRANO GOMEZ, CLAUDIA VICTORIA
AU - Bando-Campos, Carlos G.
AU - Cofas-Vargas, Luis F.
AU - Coronado-Aceves, Enrique W.
AU - González-Hernández, Ricardo A.
AU - Hernández-Peralta, Pablo
AU - Juárez-López, Daniel
AU - Ortega-Portilla, Paola A.
AU - Restrepo-Pineda, Sara
AU - Zelada-Cordero, Patricio
AU - Trujillo-Roldán, Mauricio A.
N1 - Funding Information:
Bando-Campos C.G. (fellowship 366135), Ortega-Portilla P.A. (fellowship 707238), Cofas-Vargas L.F. (fellowship 508395), and Zelada-Cordero P. (fellowship 749447) are doctoral students from Programa de Doctorado en Ciencias Bioquímicas, Universidad Nacional Autónoma de México (UNAM). González-Hernández R.A. (fellowship 717832), Juárez-López D. (fellowship 388590), and Restrepo-Pineda S. (fellowship 589949) are doctoral students from Programa de Doctorado en Ciencias Biológicas, UNAM. Hernández-Peralta P. (fellowship 394569) is a student from Doctorado en Ciencias de la Producción y de la Salud Animal, UNAM. All received fellowships from “Consejo Nacional de Ciencia y Tecnología” CONACYT. Coronado-Aceves E.W. thanks “Dirección General de Asuntos del Personal Académico (UNAM)” for the post-doctoral fellowship.
Funding Information:
This work was supported by “Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica, Universidad Nacional Autónoma de México” (PAPIIT-UNAM IV-201220, Identification of antibody sequences from recovered and asymptomatic Mexican COVID-19 patients, and development of recombinant monoclonal antibodies as a possible treatment -Identificación de secuencias de anticuerpos de pacientes COVID-19 mexicanos recuperados y asintomáticos, y desarrollo de anticuerpos monoclonales recombinantes: posible tratamiento -). Funding sources had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This work was supported by project 1200962 FONDECYT (Chile) to CA.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - SARS-CoV-2 is a novel β-coronavirus that caused the COVID-19 pandemic disease, which spread rapidly, infecting more than 134 million people, and killing almost 2.9 million thus far. Based on the urgent need for therapeutic and prophylactic strategies, the identification and characterization of antibodies has been accelerated, since they have been fundamental in treating other viral diseases. Here, we summarized in an integrative manner the present understanding of the immune response and physiopathology caused by SARS-CoV-2, including the activation of the humoral immune response in SARS-CoV-2 infection and therefore, the synthesis of antibodies. Furthermore, we also discussed about the antibodies that can be generated in COVID-19 convalescent sera and their associated clinical studies, including a detailed characterization of a variety of human antibodies and identification of antibodies from other sources, which have powerful neutralizing capacities. Accordingly, the development of effective treatments to mitigate COVID-19 is expected. Finally, we reviewed the challenges faced in producing potential therapeutic antibodies and nanobodies by cell factories at an industrial level while ensuring their quality, efficacy, and safety.
AB - SARS-CoV-2 is a novel β-coronavirus that caused the COVID-19 pandemic disease, which spread rapidly, infecting more than 134 million people, and killing almost 2.9 million thus far. Based on the urgent need for therapeutic and prophylactic strategies, the identification and characterization of antibodies has been accelerated, since they have been fundamental in treating other viral diseases. Here, we summarized in an integrative manner the present understanding of the immune response and physiopathology caused by SARS-CoV-2, including the activation of the humoral immune response in SARS-CoV-2 infection and therefore, the synthesis of antibodies. Furthermore, we also discussed about the antibodies that can be generated in COVID-19 convalescent sera and their associated clinical studies, including a detailed characterization of a variety of human antibodies and identification of antibodies from other sources, which have powerful neutralizing capacities. Accordingly, the development of effective treatments to mitigate COVID-19 is expected. Finally, we reviewed the challenges faced in producing potential therapeutic antibodies and nanobodies by cell factories at an industrial level while ensuring their quality, efficacy, and safety.
UR - http://www.scopus.com/inward/record.url?scp=85104765543&partnerID=8YFLogxK
U2 - 10.1186/s12934-021-01576-5
DO - 10.1186/s12934-021-01576-5
M3 - Review article
C2 - 33888152
AN - SCOPUS:85104765543
VL - 20
JO - Microbial Cell Factories
JF - Microbial Cell Factories
SN - 1475-2859
IS - 1
M1 - 88
ER -
